Clinical Trials Browser

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT03932253 2024-03-27

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Phase 1 Suspended

79 enrolled

Dermatologic

Melanoma

NCT05756556 2024-02-01

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Phase 2 Suspended

68 enrolled

Dermatologic

Melanoma

NCT05138458 2023-11-13

IMAGINE

Phase 1/2 Suspended

40 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

Phase 2 Suspended

6 enrolled

Dermatologic

Melanoma

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Phase 1/2 Suspended

24 enrolled

Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Phase 1 Suspended

21 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01988831 2019-05-10

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

Phase 2 Suspended

450 enrolled

Dermatologic

Melanoma, Recurrence

NCT01841463 2014-09-04

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Phase 1 Suspended

100 enrolled

Dermatologic

Melanoma

NCT00278122 2013-12-10

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Suspended

42 enrolled

Dermatologic

Melanoma

NCT00515970 2010-06-15

Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas

Phase NA Suspended

400 enrolled

Dermatologic

Carcinoma, Basal Cell, Recurrence

NCT00160992 2005-09-12

Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients

Phase 1 Suspended

6 enrolled

Dermatologic

Melanoma

NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

Phase 1/2 Suspended

48 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

NCT00042497 2005-06-24

Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

Phase 2 Suspended

60 enrolled

Dermatologic

Melanoma

Clinical Trials

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

DNX-2440 for Resectable Colorectal Liver Metastasis

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

IMAGINE

Neoadjuvant T-VEC in High Risk Early Melanoma

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas

Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma